The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Open accessAbstract
BACKGROUND: Etanercept, a soluble tumor necrosis factor receptor, has been shown to lessen disease severity in adult patients with psoriasis. We assessed the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis. METHODS: In this 48-week study, 211 patients with psoriasis (4 to 17 years of age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body weight (to a maximum of 50 mg), followed by 24 weeks of once-weekly open-label etanercept. At week 36, 138 patients underwent a second randomization to placebo or etanercept to investigate the effects of withdrawal and retreatment. The primary end point was 75% or greater improvement from baseline in the psoriasis area-and-severity index (PASI 75) at week 12. Secondary end points included PASI 50, PASI 90, physician's global assessment of clear or almost clear of disease, and safety assessments. RESULTS: At week 12, 57% of patients receiving etanercept achieved PASI 75, as compared with 11% of those receiving placebo (P<0.001). A significantly higher proportion of patients in the etanercept group than in the placebo group had PASI 50 (75% vs. 23%), PASI 90 (27% vs. 7%), and a physician's global assessment of clear or almost clear (53% vs. 13%) at week 12 (P<0.001). At week 36, after 24 weeks of open-label etanercept, rates of PASI 75 were 68% and 65% for patients initially assigned to etanercept and placebo, respectively. During the withdrawal period from week 36 to week 48, response was lost by 29 of 69 patients (42%) assigned to placebo at the second randomization. Four serious adverse events (including three infections) occurred in three patients during treatment with open-label etanercept; all resolved without sequelae. CONCLUSIONS: Etanercept significantly reduced disease severity in children and adolescents with moderate-to-severe plaque psoriasis. (ClinicalTrials.gov number, NCT00078819 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Self-citationThe Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use
LEWIS-JONES, M. S., & FINLAY, A. Y. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb16953.x · Cited by 1,051
Gupta, & Gupta (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02511.x · Cited by 864
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Disease concomitance in psoriasis
Henseler, T., & Christophers, E. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)91336-x · Cited by 678
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
Sommer, D. M., Jenisch, S., Suchan, M., Christophers, E., & Weichenthal, M. (2006) · Archives of Dermatological Research · doi:10.1007/s00403-006-0703-z · Cited by 667
Impact of Obesity and Smoking on Psoriasis Presentation and Management
Herron, M. D., Hinckley, M., Hoffman, M. S., Papenfuss, J., Hansen, C. B., Callis, K. P., & Krueger, G. G. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.12.1527 · Cited by 504
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Gottlieb, A. B. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.12.1627 · Cited by 470
Self-citationA Comparative Study of Pediatric Onset Psoriasis with Adult Onset Psoriasis
Raychaudhuri, S. P., & Gross, J. (2000) · Pediatric Dermatology · doi:10.1046/j.1525-1470.2000.01746.x · Cited by 313
Childhood Psoriasis: A Clinical Review of 1262 Cases
Morris, A., Rogers, M., Fischer, G. O., & Williams, K. J. (2001) · Pediatric Dermatology · doi:10.1046/j.1525-1470.2001.018003188.x · Cited by 312
SUICIDAL IDEATION IN PSORIASIS
GUPTA, M. A., SCHORK, N. J., GUPTA, A. K., KIRKBY, S., & ELLIS, C. N. (1993) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1993.tb02790.x · Cited by 265
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Wakkee, M., Thio, H. B., Prens, E. P., Sijbrands, E. J. G., & Neumann, H. A. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.07.011 · Cited by 240
Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
Lebwohl, M., Ellis, C., Gottlieb, A., Koo, J., Krueger, G., Linden, K., Shupack, J., & Weinstein, G. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70325-1 · Cited by 187
Self-citationOral retinoid therapy for dermatologic conditions in children and adolescents
Brecher, A. R., & Orlow, S. J. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/s0190-9622(03)01564-0 · Cited by 158
Metabolic disorders in patients with psoriasis and psoriatic arthritis
Mallbris, L., Ritchlin, C. T., & Ståhle, M. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0065-8 · Cited by 146
Pediatric psoriasis and psoriatic arthritis
Lewkowicz, D., & Gottlieb, A. B. (2004) · Dermatologic Therapy · doi:10.1111/j.1396-0296.2004.04039.x · Cited by 65
Self-citationThe Skinny on Psoriasis and Obesity
McGowan, J. W., Pearce, D. J., Chen, J. L., Richmond, D., Balkrishnan, R., & Feldman, S. R. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.12.1601 · Cited by 42
Cited by
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review
Armstrong, A. W., & Read, C. (2020) · JAMA · doi:10.1001/jama.2020.4006 · Cited by 2,335
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationGuidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Self-citationAlinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Self-citationSolovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Metadata
- Authors
- Paller, A. S., Siegfried, E. C., Langley, R. G., Gottlieb, A. B., Pariser, D., Landells, I., Hebert, A. A., Eichenfield, L. F., Patel, V., Creamer, K., & Jahreis, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-01-17
- Volume
- 358
- Issue
- 3
- Pages
- 241-251
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168503185
- Cited by
- 391
- References
- 20
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.